Copyright © Inderes 2011 - present. All rights reserved.

Intervacc

0.62 SEK

+0.32 %

Less than 1K followers

IVACC

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

+0.32 %
-29.63 %
-32.90 %
-30.26 %
-47.72 %
-42.59 %
-93.10 %
-98.97 %
-88.79 %

Intervacc is an animal health group that develops vaccines for animals. The company develops and sells vaccines against animal diseases based on its own technology platform with fused recombinant proteins. Sales are currently carried out through its own organization in the Nordic region and through its partner Dechra Pharmaceuticals in the rest of Europe. The company's headquarters are located in Hägersten.

Read more
Market cap
211.3M SEK
Turnover
412.31K SEK
Revenue
20.09M
EBIT %
-415.7 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
13/5
2026

Interim report Q1'26

13/5
2026

General meeting '26

20/8
2026

Interim report Q2'26

ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
Intervacc Q2: Net sales 1.9 M (SEK) Operating loss -18 M Net loss for the period -18 M To put it plainly, a total fiasco. International sales of the miracle vaccine are a ridiculous 160 thousand euros, which is on the same level as the turnover of some local car repair shop in Kajaani...
8/31/2023, 6:45 AM
by pt99659
7
Its time will surely come. The product is very good in terms of its effectiveness; its need is just somewhat relative. Adoption takes its time. Sales are indeed slowly growing, but USA approvals are needed (as always in pharma) to truly make a profit. That will still take a couple...
10/14/2025, 5:19 PM
by Clark kent
2
Offering terms published. In a week, shares can be subscribed at a price of 4.10 SEK. Dilution 33%
5/16/2023, 8:37 AM
by pt99659
2
Hmm. Still, more sales in the UK in 2-3/23 than in 8/22-1/23. Things take time. Have expectations been unrealistic? -effectiveness in the field seems even better than in trials -no side effects ? The US is tight-lipped, no word yet on whether a local study is needed. Currently, a...
5/3/2023, 10:10 AM
by Clark kent
2
It’s interesting that the commercialization project for the vaccine product continues, with more countries in the distribution scope, etc. In itself, the company’s stock price is at rock bottom, if not below the basement floor. Inderes Intervacc and Dechra extend distribution agreement...
10/14/2025, 3:08 PM
by veronmaksaja
1
It is worth noting that the customer is conservative. The product is very good; the marketing work just needs to be done. For those with a risk tolerance, there are good opportunities to buy the stock. Those with lower risk tolerance should wait for US marketing authorization; there...
8/31/2023, 3:08 PM
by Clark kent
1
Considering the dilution, the range I pulled out of a hat back then is now 20-26 SEK, while Erik Penser’s new analysis puts it at 26-28 SEK :D. Buying is on pause for now; these tend to drift easily toward the offering price even though it makes no sense. First an overshoot, then...
5/16/2023, 1:09 PM
by Clark kent
1
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.